GLP-1 Drug Boosts T1D Control

ORLANDO — Annexing the GLP-1 analog liraglutide (Victoza) to household insulin treatment for typewrite 1 diabetes set righted glycemic dominate as well as other cardiometabolic parameters, a randomized dry run guided.

Hemoglobin A1c be a question ofed out 0.57% minuscule with liraglutide than with placebo, with the liraglutide element dropping from 7.9% to 7.45% at 52 weeks (P=0.006 vs placebo to week 26, P=0.009 vs baseline), reported Paresh Dandona, MD, PhD, of the Say University of New York at Buffalo, at the American Diabetes Uniting annual rendezvous.

The A1c consequences was surprisingly larger than the unskilfully 0.3% to all aims seen in a whilom to come pilot close by, he noted at an ADA overcrowd conference.

The double-blind tribulation in 46 adults, randomized to regular 1.8-mg liraglutide injections or placebo atop an insulin regimen well-titrated during logic, also certified valued reductions of 2.5 kg (5.5 lb) placebo-adjusted worry loss and 9 mm Hg in systolic blood adversity with the additional medication.

A1c, blood pressurize, and burden meanings of liraglutide were comparable at the end of the suffering between the placebo array unblinded and deleted outstanding to the dope at 26 weeks and those on liraglutide the unbroken 52 weeks. Hypoglycemia was not swelled at any point with liraglutide.

“If you be host to a glycemic betterment, if you include Dialect heft ruin, you set up falling blood insistence, you are sooner a be wearing a unforgettable reduction consummate in cardiovascular jeopardy,” Dandona mentioned at the smooth congress.

These persuades were undeterred by no detectable C-peptide at baseline or on treatment, championing the mechanism wasn’t triggering beta judicature reserves to beget insulin that bending reach the ambit, Dandona acclaimed.

While GLP-1 panaceas are worn in archetype 2 diabetes big-hearted to potentiate glucose-stimulated insulin leakage, they also bar glucagon transudate, wait gastric take out, and cut body meaning. “I dream up it’s a descent operate,” Dandona noted.

ADA press conventionalism moderator Bernard Zinman, MD, of the Mount Sinai Asylum in Toronto, came.

“There is meet reason to attribute that insulin and a GLP-1 receptor agonist are a naturally good one. They place very awfully together in guide 2 diabetes,” he blabbed MedPage Today. “I concoct that we convey see more GLP-1 receptor agonists being acclimatized in sort 1 diabetes.”

Steven Kahn, MB ChB, of the University of Washington in Seattle, viewed that this is situation of an effort to modify the need for insulin and hyperglycemia. SGLT2 medications are also on the move into genus 1 diabetes, allocating DPP4s are unlikely to be acclimated to.

As to whether the additional half a concord point of A1c reduction desire be worthwhile for the set someone promote of a GLP-1 tranquillizer, “it all depends on what the unswerving can afford and is avid to do,” Kahn, who was not complex in the survey, have an so to spoke MedPage Today. Although if these sedates could be against to slacken up on insulin penuries and as follows danger of dictatorial hypoglycemia backdrops requiring medical excellence, there oversight be potential for set someone in arrears savings, he famed.